The Institute of Vaccines and Medical Biologicals (IVAC) in Vietnam recently conducted a vaccine study concluding that a potential counter to pandemic threats from A(H5N1) influenza may also involve priming the target population with A(H5N1) vaccine, and after that boosting with a dose of the pandemic vaccine at the beginning of the pandemic.
A Phase II/III study conducted in Vietnam, the results were published in December 2019. The study question was, “If an influenza pandemic were to occur, would there be a shortfall of vaccines for avian influenza A(HFN1).” The study was conducted in Vietnam from 2016 to 2017, with 630 randomized participants that received the IVACFLU-A/H5N1 vaccine candidate, reported PrecisionVaccinations.
The investigational vaccine represents an inactivated whole virion monovalent (A(H5N1) influence vaccine yielded in embryonated eggs inactivated with formaldehyde and formulated with aluminum hydroxide.
Sponsored by the Institute of Vaccines and Medical Biologicals collaborators included the National Institute of Hygiene and Epidemiology (Vietnam), World Health Organization, Department of Health and Human Services, PATH and FHI360.
The following research sites were involved with this Vietnamese vaccine study:
· Hai Phong Provincial Preventive Medicine Center Haiphong, Hai Phong, Vietnam (Phase III)
· Khanh Hoa Provincial Health Department, Nha Trang, Khanh Hoa, Vietnam (Phase II)
Tran N Duong, MD, PhD National Institute of Hygiene and Epidemiology, Vietnam